| Trial ID: | L4783 |
| Source ID: | NCT00205738
|
| Associated Drug: |
Risperidone, Olanzapine
|
| Title: |
Janssen - Glucose Regulation/Risp/Olanz
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Schizophrenia|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Risperidone, Olanzapine
|
| Outcome Measures: |
Primary: Effects of olanzapine/risperidone/haloperidol on glucose regulation. | Secondary: Explore Treatment-related effects on glucose effectiveness.
|
| Sponsor/Collaborators: |
Sponsor: Washington University School of Medicine | Collaborators: Janssen, LP
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-07
|
| Completion Date: |
2006-10
|
| Results First Posted: |
|
| Last Update Posted: |
2014-03-13
|
| Locations: |
Washington University School of Medicine, Psychiatry Dept., St. Louis, Missouri, 63110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00205738
|
